Multiple myeloma (MM) remains mostly incurable despite the recent progress in 
the treatment strategy. One of novel fields for anti-MM therapeutic strategy is 
the development of immunotherapy using monoclonal antibodies (MoAbs) against 
myeloma-specific antigens. This article focuses on the basic and clinical 
aspects of several emerging and promising novel MoAbs for MM, such as elotuzumab 
which targets CS1 and daratumumab which targets CD38. Both antigens are highly 
expressed in more than 90% of MM patients, and the clinical trials have shown 
promising anti-MM effects, especially in combination with immunomodulatory agent 
lenalidomide. We also discuss the characteristics and the results of clinical 
trials of other MoAbs, such as tabalumab against B cell activating factor or 
dacetuzumab against CD40, being developed for MM.